Doctors Without Borders demands transparency from GSK on licensing agreements for preventative HIV treatment
GSK has signed licensed agreements with three companies to manufacture generic versions of its preventative HIV medicine for distribution in lower-income countries but calls for increased transparency is putting pressure on the drugmaker.
British drugmaker and pharmaceutical company GSK has signed three deals with separate companies to allow the manufacturing of generic versions of its HIV prevention medicine, cabotegravir, for use in low-income countries.
In a statement, GSK’s HIV treatment division ViiV Healthcare waived intellectual property rights with voluntary licenses issued to Aurobindo Pharma, Cipla, and Viatris. The licenses will give the rights to distribute generic versions of cabotegravir, which is currently distributed under the brand name Vocabria. Indian-based drugmaker Cipla will also be given rights to manufacture the injections in India, with plans to expand manufacturing to South Africa. The generic drug will be supplied to 90 countries dependent on regulatory approvals and could be available as an injection to lower-income countries as early as 2026. Plans were announced last July 2022 for GSK to partner with a UN-backed healthcare organisation to bring novel HIV therapies faster and earlier to lower-income nations than previous HIV treatments.
Pre-exposure prophylaxis (PrEP) remains the most effective way for an at-risk HIV-negative individual to decrease the risk of potential infection. Until recently, the only available form of PrEP was a once-daily pill, which could undermine patient adherence. An injection once every two months such as cabotegravir would ease this burden and provide a more discreet treatment option.
The 1990s and early 2000s saw the deaths of millions of individuals in Africa during the HIV/AIDS crisis. Treatments readily available in wealthier countries were unavailable for use across the African continent. Medical NGO Médecins Sans Frontières/Doctors Without Borders (MSF) had been in negotiations with ViiV to ensure an adequate supply of the drug to lower-income nations, however, were unable to confirm or meet the demand. There have been calls for the GSK division to provide increased transparency for cabotegravir’s manufacturing and procurement, which have been met with evasive responses from the drugmaker. In a statement for MSF, Helen Bygrave, a chronic disease advisor for MSF’s Access Campaign, stated that “ViiV should be ashamed: it has a lifesaving HIV prevention drug at its fingertips but is failing to ensure there’s enough available for people who need it. They’re providing no transparency as to where currently available supplies of [cabotegravir] are being used.”
A spokesperson for GSK responded on their shared ambition with MSF to enable adequate access to the drug, and would plan to update partners such as MSF in the coming weeks: “We are moving at pace to increase capacity to meet the demand.”
Sources:
1. GSK licenses companies to make cheap copies of HIV prevention drug [Accessed April 4 2023] https://www.reuters.com/business/healthcare-pharmaceuticals/gsk-licenses-companies-make-cheap-copies-hiv-prevention-drug-2023-03-30/
2. Pharmaceutical company ViiV must provide transparency on HIV prevention drug [Accessed April 4 2023] https://www.msf.org/pharmaceutical-corporation-viiv-must-provide-transparency-life-saving-hiv-prevention-drug
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance